<DOC>
	<DOC>NCT00348361</DOC>
	<brief_summary>This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.</brief_summary>
	<brief_title>Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion criteria: No signs or symptoms of rhinitis outside of the relevant airborne allergen season. Exclusion criteria: History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments. Symptoms of rhinitis at inclusion indicated by total VAS score of &gt;40 for the combined symptoms scores for blockage, rhinorrhoea, sneezing, itching) or a single symptom with a VAS score &gt;20. Subjects not showing a nasal response to allergen concentration =&lt; 10,000 BU/ml. Subjects with positive skin prick test for Dust House Mite.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Hay fever</keyword>
	<keyword>biomarkers</keyword>
</DOC>